



SARCLISA[®]

(isatuximab-irfc)

Sarclisa is a novel monoclonal antibody directed against the CD38 receptor on the surface of myeloma cells. This is described as a targeted anti-myeloma therapy. Sarclisa both kills myeloma cells directly and recruits surrounding immune cells to enhance the killing process.

Approved indication for Sarclisa

The US Food and Drug Administration (FDA) approved Sarclisa in combination with the immunomodulatory drug Pomalyst[®] (pomalidomide) and the steroid dexamethasone (Isa-Pd) for patients with relapsed refractory myeloma who have received Revlimid[®] (lenalidomide) and a proteasome inhibitor (such as Velcade[®], Ninlaro[®], or Kyprolis[®]).

Dose and schedule for Isa-Pd

- **Sarclisa** is given as an intravenous infusion at a dose of 10 mg/kg every week for 4 weeks, then every 2 weeks. The first and second infusions take about 3–4 hours, but the remaining infusions are typically 75 minutes.
- **Pomalyst** is taken by mouth in capsule form, 4 mg on days 1–21 of every 28-day cycle.
- **Dexamethasone** can be taken by mouth in tablet form or as an intravenous infusion, 40 mg once weekly, and for patients over 75 years of age, 20 mg once weekly.

(continues on reverse side)

Possible side effects of Isa-Pd

The most common side effects (occurring in $\geq 20\%$ of patients) include the following:

- **Neutropenia:** Your white blood cell count and percentage of neutrophils will be monitored to make sure the number of neutrophils does not drop too low.
- **Upper respiratory tract infection and pneumonia:** Be alert for any fever, cough, or flu-like symptoms. Contact your doctor immediately if concerned.
- **Infusion reactions:** Medications are given before and during Sarclisa infusions to minimize the risk of infusion reactions.
- **Diarrhea:** Be sure to drink a sufficient amount of water and contact your doctor if you experience dizziness, light-headedness, and/or fainting.

Access and support resources

To explore the access and support resources for Sarclisa that may be available for eligible patients, please call **1.833.930.2273** or visit **SanofiCareAssist.com/Sarclisa**.

As always, the IMF urges you to discuss all medical issues with your doctor, and to contact the IMF with your myeloma questions and concerns.



**INTERNATIONAL
MYELOMA
FOUNDATION**

International Myeloma Foundation

12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA

818.487.7455 800.452.CURE myeloma.org

Improving Lives **Finding the Cure**[®]